Fluticasone furoate

Fluticasone Furoate is the furoate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with anti-allergic, anti-inflammatory and anti-pruritic effects. Upon administration, fluticasone binds to and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2 and the cascade of reactions involved in the synthesis of inflammatory mediators, including prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, which leads to dephosphorylation and inactivation of Jun N-terminal kinase and directly inhibits c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibiting the transcription of cyclooxygenase 2 (COX-2), that is essential for prostaglandin production. It is grouped under the following drug class(es): Corticosteroids and Steroids. Its therapeutic use is listed as anti-asthmatic agents. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Veramyst, Avamys, Allermist, Furamist and Arnuity Ellipta. Its PubChem CID is 9854489.

CAS No 397864-44-7
Molecular Formula C27H29F3O6S
Molecular Weight 538.57 g/mol
Synonyms [(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate

Frequently Asked Questions